Search

Displaying results 1141 - 1150 of 2452 in total
  1. Drug

    Fennel

    go.drugbank.com/drugs/DB15615
    Approved

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors
  2. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–assoc...

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  3. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although mult...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Fenchone

    go.drugbank.com/drugs/DB15918
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  5. Drug

    Homochlorcyclizine

    go.drugbank.com/drugs/DB15979
    Investigational

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    Garlic oil

    go.drugbank.com/drugs/DB15989
    Investigational

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  7. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization du...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  8. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the blood and to various extracerebra...

    Mixtures: LEVODOPA P BENS AL 100/25, LEVODOPA P BENS AL 100/25
  10. Drug

    Lefamulin

    go.drugbank.com/drugs/DB12825
    Approved

    Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is av...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates